# A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

> **NCT01891747** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Temozolomide
- **DIETARY_SUPPLEMENT:** Vitamin C

## Key facts

- **NCT ID:** NCT01891747
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-06
- **Final completion:** 2022-01-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01891747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01891747, "A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01891747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*